7,541.40

-38.67

-0.51%

51,983.98

+213.67

+0.41%

25,164.32

-272.68

-1.07%

2,805.92

-5.93

-0.21%

4.8940

-0.0350

-0.71%

21.40

+1.98

+10.18%

3,955.80

+56.90

+1.46%

76,726.70

-1,046.36

-1.35%

Crude Oil Dec 26

95.95

-8.17

-7.85%

US Private Equity

10,850.63

-82.20

-0.75%

Milan - Delayed Quote EUR

Gefran S.p.A. (GE.MI)

11.15 -0.05 (-0.45%)

At close: 5:35:09 PM GMT+1

Loading Chart for GE.MI

Chart Range Bar

Interval:

In partnership with ChartIQ

Deutsche Bank turns bearish on Novartis as shares recover failed trial losses

Deutsche Bank turns bearish on Novartis as shares recover failed trial losses

Novartis (SWX:NOVN) Reports Longer Survival In Advanced Kidney Cancer Trial

Novartis (SWX:NOVN) Reports Longer Survival In Advanced Kidney Cancer Trial

St. Galler Kantonalbank (SWX:SGKN) Stock Looks Reasonable With Moderate Excess Returns

St. Galler Kantonalbank (SWX:SGKN) Stock Looks Reasonable With Moderate Excess Returns

3 Oil Stocks Investors Are Screening As Brent Forecasts Move Higher

3 Oil Stocks Investors Are Screening As Brent Forecasts Move Higher

French Bank Stocks Under Pressure After Fitch Warning

French Bank Stocks Under Pressure After Fitch Warning

All You Need to Know About Novartis (NVS) Rating Upgrade to Buy

All You Need to Know About Novartis (NVS) Rating Upgrade to Buy

Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Report 2026 | Capitalize on $11.91B Market as Novartis, Voyager and Affinia Accelerate Engineered Capsids

Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Report 2026 | Capitalize on $11.91B Market as Novartis, Voyager and Affinia Accelerate Engineered Capsids

Global Gene Silencing Therapeutics Market Report 2026-2030 | Capitalize on 16.3% CAGR as Novartis, Alnylam, Ionis, Sarepta, and Arrowhead Accelerate RNA Delivery

Global Gene Silencing Therapeutics Market Report 2026-2030 | Capitalize on 16.3% CAGR as Novartis, Alnylam, Ionis, Sarepta, and Arrowhead Accelerate RNA Delivery

AstraZeneca Has an $80 Billion Dream and a Plan to Fix Its Stalling Stock

AstraZeneca Has an $80 Billion Dream and a Plan to Fix Its Stalling Stock

ALNY Stock Down 25% Despite Q3 Earnings Beat on Demand Growth Concerns

ALNY Stock Down 25% Despite Q3 Earnings Beat on Demand Growth Concerns

Is Avantor (AVTR) Stock Outpacing Its Medical Peers This Year?

Is Avantor (AVTR) Stock Outpacing Its Medical Peers This Year?

Mobilize your Website

View Site in Mobile | Classic

Share by: